Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) issued its earnings results on Thursday. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.03, Briefing.com reports. The company had revenue of $16.51 million for the quarter, compared to the consensus estimate of $13.93 million. Kymera Therapeutics had a negative net […]
HC Wainwright reissued their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a $85.00 target price on the stock. KYMR has been the subject of several other reports. Truist Financial started coverage on Kymera Therapeutics in a […]
Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its price objective increased by Credit Suisse Group from $36.00 to $37.00 in a research report sent to investors on Friday morning, Benzinga reports. Credit Suisse Group currently has a neutral rating on the stock. A number of other brokerages also recently issued reports on KYMR. Raymond James […]
AtonRa Partners cut its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 12.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,779 shares of the company’s stock after selling 3,346 shares during the period. AtonRa Partners’ […]
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) will be announcing its earnings results before the market opens on Thursday, August 3rd. Analysts expect the company to announce earnings of ($0.70) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link. Kymera Therapeutics (NASDAQ:KYMR […]